Nicholas Investment Partners LP Purchases Shares of 131,133 Vaxcyte, Inc. $PCVX

Posted by Francis Steltz on Aug 25th, 2026

Nicholas Investment Partners LP acquired a new stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX – Free Report) in the second quarter, Holdings Channel.com reports. The fund acquired 131,133 shares of the company’s stock, valued at approximately $7,623,000.

Several other large investors have also modified their holdings of the stock. Smartleaf Asset Management LLC raised its holdings in Vaxcyte by 156.2% during the 4th quarter. Smartleaf Asset Management LLC now owns 597 shares of the company’s stock worth $27,000 after buying an additional 364 shares during the period. Caitong International Asset Management Co. Ltd boosted its holdings in shares of Vaxcyte by 1,463.4% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 641 shares of the company’s stock worth $30,000 after buying an additional 600 shares during the period. EverSource Wealth Advisors LLC increased its position in shares of Vaxcyte by 33.0% in the fourth quarter. EverSource Wealth Advisors LLC now owns 741 shares of the company’s stock worth $34,000 after acquiring an additional 184 shares in the last quarter. Capital Advisors Ltd. LLC purchased a new position in shares of Vaxcyte in the first quarter worth approximately $58,000. Finally, Allworth Financial LP acquired a new stake in shares of Vaxcyte during the second quarter valued at approximately $75,000. 96.78% of the stock is owned by institutional investors.

Insider Activity at Vaxcyte

In other Vaxcyte news, COO Jim Wassil sold 2,250 shares of the company’s stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $53.86, for a total value of $121,185.00. Following the transaction, the chief operating officer owned 157,541 shares in the company, valued at approximately $8,485,158.26. This represents a 1.41% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew Guggenhime sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $53.89, for a total transaction of $538,900.00. Following the completion of the transaction, the chief financial officer owned 105,176 shares in the company, valued at approximately $5,667,934.64. This represents a 8.68% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 120,646 shares of company stock valued at $6,570,810 over the last ninety days. 3.30% of the stock is owned by company insiders.

Vaxcyte Trading Down 1.2%

Shares of Vaxcyte stock opened at $61.87 on Tuesday. Vaxcyte, Inc. has a 1 year low of $29.87 and a 1 year high of $65.00. The company has a market cap of $9.21 billion, a P/E ratio of -8.11 and a beta of 1.23. The stock has a 50-day moving average price of $56.67 and a 200 day moving average price of $55.84.

Vaxcyte (NASDAQ:PCVX – Get Free Report) last released its earnings results on Wednesday, August 5th. The company reported ($1.97) earnings per share for the quarter, beating the consensus estimate of ($2.06) by $0.09. During the same period in the previous year, the firm posted ($1.22) EPS. On average, equities analysts forecast that Vaxcyte, Inc. will post -7.6 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on PCVX shares. Zacks Research upgraded shares of Vaxcyte from a “strong sell” rating to a “hold” rating in a research report on Wednesday, August 12th. Wall Street Zen upgraded shares of Vaxcyte from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 8th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Vaxcyte in a research note on Monday, July 6th. Five research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $86.00.

View Our Latest Stock Analysis on Vaxcyte

Vaxcyte Profile

(Free Report)

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.